A Phase II study of Cisplatin and Pemetrexed for Advanced Non-Small(Non squamous cell)Lung Cancer
Phase 2
- Conditions
- Advanced Non-Small Cell (Non squamous cell)lung Cancer
- Registration Number
- JPRN-UMIN000002847
- Lead Sponsor
- Thoracic Medical oncology Thoracic center Cancer Institute Hospital Japanese Foundation for cancer research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
A recognized ILD or pulmonary fibrosis on X-rays.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ORR
- Secondary Outcome Measures
Name Time Method toxicity,PFS,OS
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted by cisplatin and pemetrexed in advanced non-squamous NSCLC in JPRN-UMIN000002847?
How does the cisplatin-pemetrexed regimen in JPRN-UMIN000002847 compare to standard-of-care therapies in non-squamous NSCLC outcomes?
Which biomarkers predict response to cisplatin and pemetrexed in advanced non-squamous NSCLC patients in JPRN-UMIN000002847?
What are the adverse event profiles and management strategies for cisplatin-pemetrexed combination in JPRN-UMIN000002847 NSCLC study?
Are there alternative platinum-based or antimetabolite combinations for non-squamous NSCLC treatment compared to JPRN-UMIN000002847 regimen?